Testing version — LOERadar is in active testing. Features and data may change.
TAZVERIK (TAZEMETOSTAT HYDROBROMIDE) | LOERadar
Not in the current Orange Book — This application is not listed in FDA's current Orange Book data files (no listed patents or exclusivities). Product and approval data shown are from FDA's Drugs@FDA database.
TAZVERIK
NDANot in Orange Book
TAZEMETOSTAT HYDROBROMIDE | N213400 | EPIZYME INC
PTAB Proceedings
No IPR/PGR/CBM challenges found at the Patent Trial and Appeal Board
Hatch-Waxman Litigation
No ANDA patent litigation cases (NOS 835) matched from PACER
Citizen Petitions
No FDA citizen petitions matched from Regulations.gov
Products (1)
#001 — 200MG
▴
TABLET;ORAL | Approved: Jun. 18, 2020
No patent or exclusivity listings for this strength.